blog

L. reuteri and Abdominal Pain: A Specific Strain, Mixed Evidence

A Reuteri event highlighted DSM 17938 for abdominal pain. See how its claims compare with mixed pediatric evidence and what adults should consider.

L. reuteri and Abdominal Pain: A Specific Strain, Mixed Evidence
Share
PinterestFacebookLinkedInWhite Reddit alien mascot face icon on transparent background.White paper airplane icon on transparent background.White stylized X logo on black background, representing the brand X/Twitter.
Oct 26, 2026
Probiotics & Supplements

On October 23, 2026, The Standard reported on a J-Health symposium for the probiotic brand Reuteri at which Iva Hojsak highlighted research linking Limosilactobacillus reuteri DSM 17938 to reduced pain intensity in functional abdominal pain. The report described an anniversary event rather than the publication of a new clinical trial.

What did earlier research say about this strain?

Before that report, the evidence was already more nuanced than a broad endorsement of probiotics for abdominal pain. The ESPGHAN position paper summarized a 2021 systematic review that included nine randomized controlled trials involving 702 children with functional abdominal pain disorders.

Within that review, six trials involving 380 children tested L. reuteri DSM 17938. The paper reported reduced pain intensity and more pain-free days in those strain-specific trials. It also noted no difference for other outcomes and concluded that firm overall evidence for probiotics in pediatric functional abdominal pain was lacking.

That combination is important. A review can identify a favorable result for a particular measurement without supporting a broad claim that a treatment reliably works. Pain intensity describes how severe pain is. Pain-free days describe time without pain, so they answer a different question.

The review's overall trial count and its strain-specific trial count are different pieces of information. Neither count should be used without saying what it includes. A review headline and a finding for one strain may therefore sound different while referring to related evidence.

For readers following supplement headlines, this is the background against which the event should be understood. The key issue is not whether any study found a benefit. It is whether the full evidence supports the specific benefit being claimed.

What does the event change about probiotic claims?

The event's main message was about specificity. According to The Standard, Hojsak said six randomized controlled trials showed reduced pain intensity in functional abdominal pain and supported the specific strain DSM 17938 rather than probiotics generally.

That is narrower than saying that any product labeled L. reuteri will deliver the same benefit. The species name is only part of the identification used in the cited research. DSM 17938 is the detail that ties the claim to the strain under discussion.

The practical change is in how the claim should be framed, not in a newly established biological explanation. The report offers no new mechanism showing how this strain changes pain. It also does not present a newly tested dietary guideline.

When interpreting a claim from this event, three details need to stay together:

  • The strain: The report's pain claim concerns L. reuteri DSM 17938 rather than the entire probiotic category.
  • The condition: The research being discussed addresses functional abdominal pain rather than digestive wellbeing in general.
  • The outcome: The highlighted result is reduced pain intensity rather than improvement in every symptom or measure.

These details are not interchangeable parts of a claim. Keeping the strain name while broadening the condition still changes what the research is being asked to support. Keeping the condition while replacing the strain creates a different evidence question.

An exact label match is therefore a starting point for evaluation rather than a guarantee of benefit. A product can name the strain discussed at an event without making every health claim on its packaging equally well supported. The next question is what the research actually measured.

For more context, DigestGenius explains how to connect probiotic findings to the question studied. Readers can also learn about checking strain details on a probiotic label. Identifying a product and evaluating its evidence are related tasks, but they are not the same task.

Where are the gaps in the evidence?

How much clinical detail was reported?

The Standard did not identify the six trials cited by Hojsak. It also did not report their participant counts or the size of the pain improvements. Confidence intervals and adverse-event data were absent as well.

Those omissions matter for interpretation. The report gives readers a conclusion without enough detail to assess how large the benefit was or how certain the estimate was. A count of positive trials is not a replacement for that missing information.

How relevant are the company's study totals?

The report also cited BioGaia/Reuteri as backed by “over 302 clinical studies” and referred separately to approximately 300 RCTs. It did not reconcile those totals or show how many studies concerned functional abdominal pain. These are company and event claims about the breadth of an evidence base rather than a condition-specific clinical review.

A large study total should not be treated as the number of trials supporting this particular pain claim. The relevant question remains which studies tested DSM 17938 for the outcome being discussed. Company-wide research activity and evidence for one clinical use need to be kept separate.

The article also includes product promotion. That context makes it especially important to separate a speaker's clinical statement from the report's wider commercial claims.

Does this evidence apply to adult symptoms?

The clinical evidence summarized in the ESPGHAN position paper concerns children with functional abdominal pain disorders. It does not establish the same effects in adults with recurring abdominal discomfort. It also does not establish benefit for bloating generally or for post-antibiotic symptoms.

For an adult reader, this is the main boundary around personal relevance. A familiar symptom name does not remove the need to check who was studied. Persistent or recurring abdominal pain belongs in a discussion with a qualified healthcare professional rather than being treated as a supplement-matching exercise.

Does the four-week comment establish a use plan?

Hojsak also said the specific strain should be taken for at least four weeks to see benefits, according to The Standard. That was an attributed statement at the event rather than a complete use protocol. The report gave no dose or formulation-specific evidence to guide individual use.

The comment should therefore not be converted into a personal trial schedule. A healthcare professional can address suitability in the context of someone's symptoms and health needs. Readers assessing a product's claims can use questions that keep supplement evidence in context without treating a headline as a prescription.

What should this mean for daily food choices?

The realistic takeaway is to be more selective about evidence rather than more restrictive about food. This event does not provide a basis for changing everyday meals or assuming that a probiotic should be added to them. It adds context to a supplement claim, not a new eating rule.

For decisions about abdominal symptoms, the useful match is between the exact strain and the condition and population studied. A label is not the final answer. The next meaningful step is a condition-specific assessment of the evidence, with qualified care where the decision is personal.

How DigestGenius helps

Strain-specific pain claims can sound more settled than the evidence behind them, a gap DigestGenius addresses through research-led education. Its free articles and in-depth resources on digestion and microbiome science help adults distinguish promising probiotic findings from established knowledge without turning an event report into a recommendation for everyone.

Explore the Blog

Sources

  1. Reuteri 21st Anniversary: Reaching New Heights in Evidence-Based Probiotics
  2. Probiotics for Pediatric GI Disorders: ESPGHAN Position ...

DigestGenius publishes research-led guidance on digestion, the gut microbiome, fiber, probiotics, gut-brain signaling, inflammation and everyday digestive wellbeing.

FacebookInstagramYouTubeXPinterest

Continue reading

New IBS Fiber Guide Puts Serving Sizes in Context
November 22, 2026
Food, Fiber & Nutrition

New IBS Fiber Guide Puts Serving Sizes in Context

read article
Why do bloating and constipation often happen together?
November 22, 2026
Bloating & Regularity

Why do bloating and constipation often happen together?

read article
How 24-Hour Body Clocks and Stress Patterns Drive Changes in Colon Activity and Microbes
November 21, 2026
Gut-Brain & Lifestyle

How 24-Hour Body Clocks and Stress Patterns Drive Changes in Colon Activity and Microbes

read article
understand your gut

Keep learning what supports a healthier gut

Explore clear, research-led guidance on digestion, the microbiome, food, fiber, probiotics and the gut-brain connection.

read the blog
Woman holding a colorful plant-rich bowl in a bright kitchen